Table I.
CDK5 expression associated with the multiple clinicopathological factors in MM
| MM | n CD | K5+ (n) | CDK5− (n) | P-value |
|---|---|---|---|---|
| Bor response | 0.020 | |||
| ≥PR | 51 | 20 | 31 | |
| SD/PD | 14 | 11 | 3 | |
| Sex | 0.896 | |||
| Male | 33 | 16 | 17 | |
| Female | 32 | 15 | 17 | |
| Age (years) | 0.870 | |||
| ≥65 | 11 | 5 | 6 | |
| <65 | 54 | 26 | 28 | |
| D-S | 0.026 | |||
| I/II | 19 | 5 | 14 | |
| III | 46 | 26 | 20 | |
| ISS | 0.291 | |||
| I | 13 | 4 | 9 | |
| II/III | 52 | 27 | 25 | |
| M protein | 0.628 | |||
| IgG | 31 | 15 | 16 | |
| non-IgG | 18 | 10 | 8 | |
| M protein | 0.063 | |||
| κ | 32 | 19 | 13 | |
| λ | 33 | 12 | 21 | |
| Plasma cells | 0.188 | |||
| ≥50% | 24 | 14 | 10 | |
| <50% | 41 | 17 | 24 | |
| HGB (g/l) | 0.135 | |||
| ≥100 | 25 | 9 | 16 | |
| <100 | 40 | 22 | 18 | |
| Ca2+ (mmol/l) | 0.927 | |||
| ≥2.65 | 15 | 7 | 8 | |
| <2.65 | 50 | 24 | 26 | |
| Cr (µmol/l) | 0.614 | |||
| ≥177 | 17 | 9 | 8 | |
| <177 | 48 | 22 | 26 |
MM, multiple myeloma; Ig, immunoglobulin; CDK, cyclin dependent kinase; Cr, creatinine; Bor, bortezomib; PR, partial response; SD, stable disease; PD, progressive disease; D-S, Durie-Salmon; ISS, International Staging System; HGB, hemoglobin; Ca, calcium.